New drug combo aims to tackle Hard-to-Treat cancers

NCT ID NCT03872947

Ongoing Disease control Sponsor: Toray Industries, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Participants receive TRK-950 plus one of several chemotherapy or immunotherapy regimens depending on their cancer type.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TRK-950
What this could lead to: If successful, this could point toward a new combination treatment option for several advanced solid tumors that are hard to treat.
What could go wrong: This is an early-phase trial, so the main goal is safety and dosing, not proof of effectiveness. The drug may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial cholangiocarcinoma colorectal cancer colorectal neoplasm fallopian tube cancer fallopian tube neoplasm gastric cancer gastric neoplasm melanoma ovarian cancer ovarian carcinoma primary peritoneal carcinoma renal cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER CHOLANGIOCARCINOMA COLORECTAL CANCER EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER GASTRIC CANCER MELANOMA OVARIAN CANCER PALPABLE SUBCUTANEOUS MALIGNANT LESIONS PRIMARY PERITONEAL CANCER RENAL CELL CARCINOMA SOLID TUMOR

Contacts and locations

Locations

AOA-HOPE

Tucson, Arizona, 85711, United States
Atlantic Health System

Morristown, New Jersey, 07960, United States
Centre Léon Bérard

Lyon, 69373, France
HOAG Memorial Hospital Presbyterian

Newport, California, 92663, United States
HonorHealth Research Institute

Scottsdale, Arizona, 85258, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Northwest Cancer Specialists

Portland, Oregon, 97227, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center)

Eugene, Oregon, 97401, United States
Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Texas Oncology - Downtown Fort Worth Cancer Center

Fort Worth, Texas, 76104, United States
Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
Virginia Cancer Specialists, PC

Leesburg, Virginia, 20176, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.